Actinium Pharmaceuticals, Inc. (ATNM)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Sandesh C. Seth M.B.A., M.S. | Chairman & CEO | 1.21M | -- | 1964 |
| Mr. Steven O'Loughlin BS | CFO & Corporate Secretary | 590k | -- | 1986 |
| Dr. Paul Diamond Esq., Ph.D. | Vice President of Patent & Legal Counsel | -- | -- | -- |
| Dr. David Gould | Senior Vice President of Corporate Development & Corporate Affairs | -- | -- | -- |
| Dr. Bernie Cunningham P.M.P., Ph.D. | Executive Director of Clinical Supply Chain & Logistics and CMC Project Management | -- | -- | -- |
| Dr. Qing Liang | VP & Head of Radiation Sciences | -- | -- | -- |
| Dr. Avinash Desai M.D. | Chief Medical Officer | -- | -- | -- |
| Ms. Jenny Hsieh | Chief Strategy Officer | -- | -- | -- |
| Ms. Sunitha Lakshminarayanan | Senior VP, Head of CMC & Product Development | -- | -- | -- |
| Ms. Elaina Haeuber | VP & Head of Clinical Operations | -- | -- | -- |
Actinium Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 49
Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, Iomab-B (I-131 apamistamab) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iomab-ACT for GeneTx and cell therapy conditioning, Actimab-A (CD33) and CLAG-M, Actimab-A (CD33) and Venetoclax, and Actimab-A (CD33) and Venetoclax with HMA. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 -SIRPa immunotherapy targeted radiotherapy; AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors; and Immedica pharma for licensed the rights to commercialize Iomab-B. The company is based in New York, New York.
Corporate Governance
Recent Events
- Apr 26, 202410-Q: Periodic Financial ReportsSee Full Filing
- Mar 29, 202410-K: Periodic Financial ReportsSee Full Filing
- Feb 02, 2024S-3/A: Offering RegistrationsSee Full Filing
- Jan 29, 2024SC 13G: Tender Offer/Acquisition ReportsSee Full Filing
- Dec 01, 20238-K: Corporate Changes & Voting MattersSee Full Filing